| Migraine Disorders
Ajovy vs Reyvow
Side-by-side clinical, coverage, and cost comparison for migraine disorders.Deep comparison between: Ajovy vs Reyvow with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsReyvow has a higher rate of injection site reactions vs Ajovy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Reyvow but not Ajovy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Ajovy
Reyvow
At A Glance
SC injection
Monthly or every 3 months
CGRP antagonist
Oral
As needed
5-HT1F receptor agonist
Indications
- Migraine Disorders
- Episodic migraine
- Migraine Disorders
Dosing
Migraine Disorders 225 mg SC monthly or 675 mg SC quarterly (three consecutive 225 mg injections) into abdomen, thigh, or upper arm.
Episodic migraine Pediatric patients 6 to 17 years weighing 45 kg or more: 225 mg SC monthly.
Migraine Disorders 50 mg, 100 mg, or 200 mg orally as needed; no more than one dose in 24 hours; wait at least 8 hours between dosing and driving or operating machinery; swallow tablets whole.
Contraindications
- Serious hypersensitivity to fremanezumab-vfrm or any excipient, including anaphylaxis and angioedema
—
Adverse Reactions
Most common (>=2%) Injection site reactions (pain, induration, erythema)
Serious Hypersensitivity reactions, hypertension, Raynaud's phenomenon
Postmarketing Anaphylactic reactions, angioedema, hypertension, Raynaud's phenomenon
Most common (>=2%) dizziness, fatigue, paresthesia, sedation, nausea and/or vomiting, muscle weakness
Serious hypersensitivity reactions including angioedema, rash, and photosensitivity reaction
Pharmacology
Fremanezumab-vfrm is a humanized monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor, thereby inhibiting CGRP-mediated signaling implicated in migraine.
5-HT1F receptor agonist; lasmiditan binds with high affinity to the 5-HT1F receptor and presumably exerts its therapeutic effects in migraine through agonist activity at this receptor, though the precise mechanism is unknown.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ajovy
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (7/12) · Qty limit (10/12)
Reyvow
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (10/12)
UnitedHealthcare
Ajovy
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (1/8) · Qty limit (1/8)
Reyvow
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (5/8) · Qty limit (4/8)
Humana
Ajovy
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Reyvow
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableHealthWell: Migraine
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Reyvow.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.